SciClone Pharmaceuticals (Holdings) Limited

SEHK:6600 Stock Report

Mkt Cap: HK$6.5b

We’ve recently updated our valuation analysis.

SciClone Pharmaceuticals (Holdings) Valuation

Is 6600 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 6600?

Other financial metrics that can be useful for relative valuation.

6600 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.6x
Enterprise Value/EBITDA3.3x
PEG Ratio-5.3x

Price to Earnings Ratio vs Peers

How does 6600's PE Ratio compare to its peers?

The above table shows the PE ratio for 6600 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average12.9x
1666 Tong Ren Tang Technologies
12.7x5.7%HK$7.5b
2877 China Shineway Pharmaceutical Group
8.2x9.4%HK$5.5b
1349 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
22.7xn/aHK$8.5b
3933 United Laboratories International Holdings
8.2x0.2%HK$9.4b
6600 SciClone Pharmaceuticals (Holdings)
6.7x-1.3%HK$6.5b

Price-To-Earnings vs Peers: 6600 is good value based on its Price-To-Earnings Ratio (6.7x) compared to the peer average (12.9x).


Price to Earnings Ratio vs Industry

How does 6600's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.0%
n/an/an/a

Price-To-Earnings vs Industry: 6600 is good value based on its Price-To-Earnings Ratio (6.7x) compared to the Hong Kong Pharmaceuticals industry average (10.5x)


Price to Earnings Ratio vs Fair Ratio

What is 6600's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

6600 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.7x
Fair PE Ratio9.9x

Price-To-Earnings vs Fair Ratio: 6600 is good value based on its Price-To-Earnings Ratio (6.7x) compared to the estimated Fair Price-To-Earnings Ratio (9.9x).


Share Price vs Fair Value

What is the Fair Price of 6600 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 6600 (HK$9.48) is trading below our estimate of fair value (HK$9.71)

Significantly Below Fair Value: 6600 is trading below fair value, but not by a significant amount.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 6600 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$9.48
HK$11.19
+18.0%
8.2%HK$12.29HK$10.04n/a3
Jan ’24HK$8.29
HK$11.28
+36.1%
11.6%HK$13.00HK$9.83n/a3
Dec ’23HK$6.11
HK$10.92
+78.8%
10.5%HK$12.46HK$9.70n/a3
Nov ’23HK$5.96
HK$10.92
+83.3%
10.5%HK$12.46HK$9.70n/a3
Oct ’23HK$6.19
HK$11.14
+80.0%
12.6%HK$12.92HK$9.50n/a3
Sep ’23HK$6.95
HK$11.14
+60.3%
12.6%HK$12.92HK$9.50n/a3
Aug ’23HK$7.50
HK$11.80
+57.4%
12.9%HK$13.00HK$9.66n/a3
Jul ’23HK$8.70
HK$11.85
+36.2%
16.9%HK$13.53HK$9.03n/a3
Jun ’23HK$8.04
HK$11.85
+47.4%
16.9%HK$13.53HK$9.03n/a3
May ’23HK$8.29
HK$11.85
+43.0%
16.9%HK$13.53HK$9.03n/a3
Apr ’23HK$8.22
HK$11.85
+44.2%
16.9%HK$13.53HK$9.03n/a3
Mar ’23HK$8.14
HK$16.41
+101.6%
11.3%HK$19.03HK$15.00n/a3
Feb ’23HK$8.40
HK$16.35
+94.7%
10.6%HK$18.79HK$14.97HK$9.483
Jan ’23HK$8.65
HK$18.15
+109.8%
11.2%HK$20.01HK$15.33HK$8.293
Dec ’22HK$8.90
HK$18.21
+104.6%
11.8%HK$20.34HK$15.26HK$6.113
Nov ’22HK$10.44
HK$18.01
+72.5%
10.2%HK$20.10HK$15.08HK$5.964
Oct ’22HK$10.40
HK$18.01
+73.1%
10.2%HK$20.10HK$15.08HK$6.194
Sep ’22HK$10.18
HK$18.27
+79.5%
11.1%HK$20.06HK$15.05HK$6.954
Aug ’22HK$11.42
HK$20.59
+80.3%
11.0%HK$24.20HK$17.97HK$7.504
Jul ’22HK$14.90
HK$20.59
+38.2%
11.0%HK$24.20HK$17.97HK$8.704
Jun ’22HK$14.70
HK$20.57
+40.0%
12.4%HK$23.96HK$17.80HK$8.043
May ’22HK$15.78
HK$20.57
+30.4%
12.4%HK$23.96HK$17.80HK$8.293

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies